AGN.c AGNPF announced last week they began screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (DMT).


The decision to investigate DMT and move it into human trials for stroke is based on multiple independent, positive preclinical studies demonstrating that DMT helps promote structural and functional neuroplasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury.


Considering they announced they were granted permission to conduct the study on the 8th, it’s impressive they’re getting underway so soon. Will be watching for any updates.


https://ir.algernonpharmaceuticals.com/news-events/press-releases/detail/167/algernon-pharmaceuticals-enters-into-a-clinical-trial